OncoLink Cancer Treatment and Resources

Oncolink Features

Find My Cancer Drug

OncoLink Cancer Treatment and Resources

Tipos de Cancer / Leucemia / Leucemia de Célula Pilosa / Recursos de NCI

Link to OncoLink

NCI CANCERLIT^® Search: Hairy Cell Leukemia - April 2002

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 1 de abril del 2002

[Hairy cell leukemia: report of 8 cases]

Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.

Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia.

Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution.

Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell

Understanding the action of interferon in hairy cell leukemia: the past as prologue.

Table of Contents

1
UI - 11892443
AU - Medini Manai Z; Meddeb B; Lakhal R; Ben Abid H; Bel HadjAli Z; Ben
TI - Othman T; Hafsia A [Hairy cell leukemia: report of 8 cases]
SO - Tunis Med 2001 Dec;79(12):681-5
AD - Service d'hematologie Hopital Aziza Othmana, Tunis.
Hairy cell leukemia haemopathy is a rare lymphoid haemopathy type B. 8 cases are reported and diagnosed at Hopital Aziza Othmana over a period of 20 years between 1979 and 1999, 7 men and one women. The mean age of the patients is 51 years, with externe ages from 42 to 81 years. 4 patients consulted for an infections and, or anaemia syndrome. The disease was revealed due to the presence of an isolated splenomegaly in other cases. At the clinical examination, the spleen is hypertrophied in 7 patients out of 8. Pancytopenia is observed in 50% of the patients. Only one patient has presented a moderated hyperleukocytosis at 11,000/mm3 related to the presence of moving on tricholeukocytes. The myelogramme is pocr. It allowed to mention the diagnosis in 6 cases out of 8. Bone Marrow biopsy revealed a diffuse infiltration by TCL with a reticulinic fibrosis in all patients. 4 patients out of 8 have been splenectomized. Cytopenies have been corrected in all patients. Only one patient has been treated by alpha Interferon for 3 years with a partial hematological response. A relapse was observed once the Interferon was stopped. With the introduction of new drugs such purine analogues. The HCL treatment has been revolutionarized thanks to the improvement of the rate of complete response (from 10% to 80% of CR). If splenectomy is still observed in HCL for splenomegalic and or severe cytopenia, our findings could be improved thanks to new purine analogues.

2
UI - 11801472
AU - Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
TI - Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
SO - Haematologica 2002 Jan;87(1):107-8
AD - Department of Hematology, University Clinical Hospital, C/ San Juan Bosco, 15 50009 Zaragoza, Spain. hemh@hcu-lblesa.es

3
UI - 11849216
AU - Bourguin-Plonquet A; Rouard H; Roudot-Thoraval F; Bellanger C; Marquet
TI - J; Delfau-Larue MH; Divine M; Farcet JP Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia.
SO - Br J Haematol 2002 Mar;116(3):595-7
AD - Service d'Immunologie Biologique, Hopital Henri Mondor, Creteil, France. anne.plonquet@hmn.ap-hop-paris.fr
Clinical studies in hairy cell leukaemia (HCL) have linked the frequent occurrence of infections due to intracellular pathogens and a profound monocytopenia. More recently, dendritic cells (DC), a subset of which are related to monocytes, were shown to be the professional antigen-presenting cells which stimulate the adaptive immune response. Using membrane markers and flow cytometry, we determined in peripheral blood whether various DC subsets and monocytes were impaired in HCL. Lymphoid and myeloid DC were virtually absent in five HCL patients with active disease. After treatment, both DC and monocytes recovered slowly. The decrease in DC suggests that defective antigen presentation could affect susceptibility to intracellular pathogens in HCL.

4
UI - 10792402
AU - Grey MR; Flanagan NG; Kelsey PR
TI - Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution.
SO - Clin Lab Haematol 2000 Apr;22(2):111-3
AD - Haematology/Oncology Unit, Blackpool Victoria Hospital NHS Trust, Blackpool, UK.
Although hairy cell leukaemia was first described 40 years ago, it is only in the last decade that newer therapeutic agents have enabled effective treatment. The purine nucleoside analogue, 2-chlorodeoxyadenosine (2-CdA) is currently considered as first-line therapy with a very high rate of complete remission. Although adverse events with 2-CdA are increasingly recognized, severe cutaneous reactions have been reported rarely. We describe two consecutive patients treated with 2-CdA for hairy cell leukaemia who both suffered extremely severe cutaneous reactions, one of which was life-threatening.

5
UI - 10552943
AU - Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M;
TI - Waldmann TA; Pastan I Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
SO - Blood 1999 Nov 15;94(10):3340-8
AD - Laboratory of Molecular Biology, the Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
We report major responses in 4 of 4 patients with hairy cell leukemia (HCL) who have recently been treated on a phase I trial with the recombinant immunotoxin LMB-2. The immunotoxin, designed to target CD25(+) malignancies, is composed of the Fv portion of the anti-Tac (anti-CD25) antibody, fused to a 38-kD truncated form of Pseudomonas exotoxin A, and has previously been called anti-Tac(Fv)-PE38. All 4 HCL patients were resistant to standard and salvage therapies for HCL, including 2-chlorodeoxyadenosine (CdA) and interferon alpha, and all patients responded to LMB-2 after a single cycle. One patient treated with 2 cycles had a complete remission (CR), with regression of HCL cells from the blood and marrow and resolution of splenomegaly and pancytopenia. As is typical for patients in CR after treatment with CdA, minimal residual disease was detectable by flow cytometry of the bone marrow aspirate. This patient has not relapsed after 11 months. Three other patients had 98% to 99.8% reductions in malignant circulating cells. These results represent a proof of principal that targeted therapy with recombinant Fv-containing proteins can be clinically useful. LMB-2 may be an effective new therapy for patients with chemotherapy-resistant CD25(+) HCL.

6
UI - 11755467
AU - Khalaf W; Maina C; Byers J; Harvey W
TI - Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested.
SO - Leuk Res 2002 Feb;26(2):169-77
AD - Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46222, USA.
The in vitro effects of interferon-alpha (IFN) on levels of secreted interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF alpha), and nuclear matrix proteins (NMP) were examined in ESKOL, a B-lymphoblastoid cell line resembling hairy cell leukemia (HCL). IFN enhances differentiation in ESKOL, decreases TNF alpha levels, decreases apoptosis, increases IL-6 levels, and down regulates the expression of several oncogenes. Vesnarinone (Ves), a TNF alpha repressor, lowers TNF-alpha and decreases apoptosis in the same cell line. ESKOL exhibits enhanced apoptosis and reduced B-cell lymphomas (Bcl-2) levels over WIL-2. IL-6 and TNFalpha have been shown to decrease and increase apoptosis in B-cells respectively; however, treatment of ESKOL with these cytokines had no significant effect on apoptosis. We suggest that IFN decreases apoptosis by mechanisms involving enhanced IL-6 and Bcl-2 levels, decreased TNF alpha and the down regulation of apoptotic oncogenes, including c-myc.

7
UI - 11839386
AU - Tallman MS
TI - Understanding the action of interferon in hairy cell leukemia: the past as prologue.
SO - Leuk Res 2002 Apr;26(4):407-8
AD - Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink Cancer Treatment and Resources

OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement